Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brightline-3: Brigimadlin + Ezabenlimab vs Chemotherapy in Advanced Soft Tissue Sarcoma
NCT06370871Phase 3Withdrawn
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of brigimadlin in undifferentiated pleomorphic sarcoma (UPS), myxofibrosarcoma (MFS), sponsored by Boehringer Ingelheim. Planned start Jun 2024; status: withdrawn.
02
Drugs
brigimadlin
03
Conditions
undifferentiated pleomorphic sarcoma (UPS)myxofibrosarcoma (MFS)
Beyond the preview
Go deeper on NCT06370871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06370871.